Form 4: Orchestra BioMed Director Acquires Stock Options

Orchestra BioMed Holdings, Inc. director Chris Cleary acquired stock options and had shares withheld for tax obligations related to RSU vesting.

Summary

• Chris Cleary, a Director at Orchestra BioMed Holdings, Inc., was involved in transactions on June 23, 2026.
• 3,510 shares of common stock were acquired, with a transaction code 'F', indicating a non-sale transaction for tax withholding.
• These shares were acquired to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs).
• No market sales occurred as a result of this transaction.
• Additionally, 42,553 stock options were acquired with an exercise price of $4.04.
• These stock options are set to vest on the one-year anniversary of the grant date, June 23, 2026, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine executive compensation transactions rather than significant financial performance or strategic shifts.

Positives

• Director Chris Cleary's acquisition of stock options indicates continued commitment and potential future upside in the company.
• The withholding of shares for tax obligations upon RSU vesting suggests that equity compensation is being utilized effectively.
• The fact that no shares were sold in the market to cover tax obligations is a positive sign, indicating the director is not liquidating holdings to meet tax liabilities.

Negatives

• The acquisition of stock options is a forward-looking statement and does not represent immediate realized value.
• The withholding of shares for tax purposes, while standard, does reduce the net number of shares received by the director.

Risks

• The stock options are subject to vesting, meaning they can be forfeited if the reporting person's continuous service is not maintained.
• The value of the stock options is directly tied to the future performance of Orchestra BioMed Holdings, Inc. stock price.

Future Outlook

The stock options acquired by Director Chris Cleary are set to vest on June 23, 2027, provided he remains in continuous service with the company. This indicates a forward-looking incentive tied to the company's future performance.

Industry Context

StockSavvy.ai notes that the issuance and acquisition of stock options and the handling of RSU vesting through share withholding are standard practices within the biotechnology and pharmaceutical sectors, reflecting common executive compensation and incentive structures.

Stakeholder Impact

• Shareholders: The transaction does not directly impact the number of outstanding shares or immediate market supply, but the director's continued incentive aligns their interests with shareholders.
• Employees: The transaction highlights the company's use of equity-based compensation, which can influence employee morale and retention.
• Management: The acquisition of options by a director reinforces their long-term commitment and potential financial upside tied to company performance.

Next Steps

• Vesting of stock options on June 23, 2027, subject to continued service.

Key Dates

Keywords

Orchestra BioMed Holdings, OBIO, Form 4, Stock Options, RSU Vesting, Tax Withholding, Director Transaction, Beneficial Ownership